FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Nusbickel Thomas 2. Issuer Name and Ticker or Trading Symbol CorMedix Inc. [ CRMD ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
EVP, Chief Commercial Officer
(Last)         (First)         (Middle)
C/O CORMEDIX INC. 300 CONNELL DRIVE,, SUITE 4200
3. Date of Earliest Transaction (MM/DD/YYYY)
5/13/2021
(Street)
BERKELEY HEIGHTS,, NJ 07922
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy Common Stock)  $7.56  5/13/2021    A     260000       (1) 5/13/2031  Common Stock  260000  $0  260000  D   
Stock Option (Right to Buy Common Stock)  $7.56  5/13/2021    A     7500       (2) 5/13/2031  Common Stock  7500  $0  7500  D   

Explanation of Responses:
(1)  The options vest as follows: 160,000 will vest over four years in four (4) equal installments on the first four anniversaries of May 13, 2021. The remaining 100,000 options vest on the achievement of certain milestones, subject to continued employment.
(2)  These options were granted on May 13, 2021. These options shall vest in full on the first anniversary of the grant date, subject to continued employment.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Nusbickel Thomas
C/O CORMEDIX INC. 300 CONNELL DRIVE,
SUITE 4200
BERKELEY HEIGHTS,, NJ 07922


EVP, Chief Commercial Officer

Signatures
/s/ Thomas Nusbickel 5/20/2021
**Signature of Reporting Person Date
CorMedix (NASDAQ:CRMD)
Historical Stock Chart
From Jun 2021 to Jul 2021 Click Here for more CorMedix Charts.
CorMedix (NASDAQ:CRMD)
Historical Stock Chart
From Jul 2020 to Jul 2021 Click Here for more CorMedix Charts.